These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34696173)

  • 1. Economic Assessment of High-Dose Versus Adjuvanted Influenza Vaccine: An Evaluation of Hospitalization Costs Based on a Cohort Study.
    van Aalst R; Gravenstein S; Mor V; Mahmud SM; Wilschut J; Postma M; Chit A
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.
    van Aalst R; Gravenstein S; Mor V; Mahmud SM; Wilschut J; Postma M; Chit A
    Vaccine; 2020 Jan; 38(2):372-379. PubMed ID: 31606249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
    Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
    Schmader KE; Liu CK; Harrington T; Rountree W; Auerbach H; Walter EB; Barnett ED; Schlaudecker EP; Todd CA; Poniewierski M; Staat MA; Wodi P; Broder KR
    JAMA Netw Open; 2021 Jan; 4(1):e2031266. PubMed ID: 33443580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019-2020 Influenza Season.
    Imran M; Puig-Barbera J; Ortiz JR; Fischer L; O'Brien D; Bonafede M; Mansi JA; Boikos C
    Open Forum Infect Dis; 2022 May; 9(5):ofac167. PubMed ID: 35493131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
    Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
    Patel SS; Bizjajeva S; Heijnen E; Oberye J
    Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States.
    Boikos C; McGovern I; Ortiz JR; Puig-Barberà J; Versage E; Haag M
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience.
    Nicolay U; Heijnen E; Nacci P; Patriarca PA; Leav B
    Int J Infect Dis; 2019 Aug; 85S():S1-S9. PubMed ID: 30926542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis.
    Lee JKH; Lam GKL; Shin T; Samson SI; Greenberg DP; Chit A
    Vaccine; 2021 Mar; 39 Suppl 1():A24-A35. PubMed ID: 33422382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19.
    Balasubramani GK; Choi WS; Nowalk MP; Zimmerman RK; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Murthy K; Jackson ML; Jackson LA; Chung JR; Spencer S; Fry AM; Patel M; Flannery B;
    Vaccine; 2020 Sep; 38(42):6562-6569. PubMed ID: 32800465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease.
    van Aalst R; Russo EM; Neupane N; Mahmud SM; Mor V; Wilschut J; Chit A; Postma M; Young-Xu Y
    Vaccine; 2019 Jul; 37(32):4499-4503. PubMed ID: 31262590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications.
    Boikos C; Imran M; Nguyen VH; Ducruet T; Sylvester GC; Mansi JA
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34451987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019-2020 Season.
    Izurieta HS; Lu M; Kelman J; Lu Y; Lindaas A; Loc J; Pratt D; Wei Y; Chillarige Y; Wernecke M; MaCurdy TE; Forshee R
    Clin Infect Dis; 2021 Dec; 73(11):e4251-e4259. PubMed ID: 33211809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis.
    Levin MJ; Divino V; Shah D; DeKoven M; Mould-Quevedo J; Pelton SI; Postma MJ
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older.
    Lindert K; Leav B; Heijnen E; Barrett J; Nicolay U
    Int J Infect Dis; 2019 Aug; 85S():S10-S17. PubMed ID: 30904674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the impact of high-dose versus standard dose influenza vaccines on hospitalization cost for cardiovascular and respiratory diseases: Economic assessment in the US Veteran population during 5 respiratory seasons using an instrumental variable method.
    van Aalst R; Russo EM; Neupane N; Mahmud SM; Wilschut J; Samson SI; Chit A; Postma M; Young-Xu Y
    Vaccine; 2021 Mar; 39 Suppl 1():A51-A55. PubMed ID: 32576459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis.
    Lee JKH; Lam GKL; Shin T; Kim J; Krishnan A; Greenberg DP; Chit A
    Expert Rev Vaccines; 2018 May; 17(5):435-443. PubMed ID: 29715054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.